

MATERIAL CHANGE REPORT

1. Name and Address of Company

Solarvest BioEnergy Inc. (“Solarvest” or the “Company”)
439 Helmcken Street,
Vancouver, B.C.
V6B 2E6

2. Date of Material Change

November 14, 2014

3. News Release

News releases with respect to this material change were disseminated on August 6, 2014 and November 17, 2014 via Marketwired.

4. Summary of Material Change

Solarvest has closed its previously announced asset purchase with Kohilo Bio Inc. (“Kohilo”), pursuant to which it acquired worldwide rights to certain patents and patent applications for a total purchase price of \$102,642.75.

5. Full Description of Material Change

On November 14, 2014, Solarvest closed a transaction to acquire worldwide rights to certain patents and patent applications from Kohilo Bio Inc. (“Kohilo”). Pursuant to the purchase agreement the total purchase price of \$102,642.75; \$70,000 of which will be paid through the issuance of 200,000 common shares at a deemed price of \$0.35 per share, and the balance of \$32,642.75 through the assumption of Kohilo’s debt.

Solarvest now holds four complementary patents:

- o **SYSTEM, METHOD, AND DEVICE FOR THE EXPRESSION OR REPRESSION OF PROTEINS:** This invention manipulates algae cell processes.
- o **METHOD OF MAKING MICROALGAL-BASED ANIMAL FOODSTUFF SUPPLEMENTS, MICROALGAL-SUPPLEMENTED ANIMAL FOODSTUFFS AND METHOD OF ANIMAL NUTRITION:** This invention relates to use of algae as a safe, biodegradable food additive to effectively deliver trace metal essential nutrients to animals.
- o **DENTAL COMPOSITION AND METHOD:** This patent covers the use of algae and/or modified algae to control the growth of dental plaque on companion animals.
- o **METHODS AND USES OF A MODIFIED CECROPIN FOR TREATING ENDOPARASITIC AND BACTERIAL INFECTIONS:** This invention relates to the use of modified anti-microbial protein (cecropin and or variant of) or nucleic acid for treating or preventing endoparasites, such as Plasmodium (malaria parasite), and bacteria.

This transaction involves certain related parties. Specifically, the principals of Kohilo are Mr. Mike Horne, who is also a director and secretary of Solarvest's wholly owned European Subsidiary, Phycobiologics (Europe) Inc. and Mr. Garth Greenham who is the brother of Gerri Greenham, Director, CEO and control person of Solarvest. Additionally, certain of the debts of Kohilo to be assumed by Solarvest include Kohilo's outstanding account with a law firm at which Kenneth A. Cawkell, Director, Chairman and Secretary of Solarvest, is a partner.

The transaction is exempt from the valuation and shareholder approval requirements of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"), since neither the fair market value of the shares issued, nor the consideration paid for the transaction, totalled more than 25% of the market capitalization of the Company before giving effect to the transaction. Specifically, this transaction is exempt from shareholder approval in accordance with section 5.7(1)(a) of MI 61-101 and no formal valuation has been conducted for this transaction in accordance with section 5.5(a) of MI 61-101. The price has been set at \$0.35 based upon the Company's trading price at the time of negotiation.

Gerri Greenham declared his interest in the transaction to the Company's Board of Directors and abstained from voting on the resolution approving the placement. Mr. Cawkell also declared his interest in the transaction to the Board. The details of this transaction were approved by the Board of Directors on July 23, 2014.

Concurrently with the closing of this transaction, Garth Greenham has been appointed as Chief Operating Officer of Solarvest, subject to Exchange approval.

The common shares issuable pursuant to the purchase agreement will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation.

For further details see the attached news releases.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

7. Omitted Information

No information has been omitted from this report on the basis that it is confidential information.

8. Executive Officer

Kenneth A. Cawkell, Secretary
Tel: (604) 684 3323

9. Date of Report

November 17, 2014

FOR IMMEDIATE RELEASE

TSX-V: SVS

SOLARVEST ACQUIRES BIOACTIVE PATENTS

Montague, PEI, November 17, 2014 – SOLARVEST BIOENERGY INC. (TSX-V:SVS) (“Solarvest”), announces that it has closed its previously announced transaction to purchase worldwide rights to certain patents and patent applications from Kohilo Bio Inc. (“Kohilo”). Pursuant to the purchase agreement the total purchase price of \$102,642.75; \$70,000 of which was paid through the issuance of 200,000 common shares at a deemed price of \$0.35 per share, and the balance of \$32,642.75 through the assumption of Kohilo’s debt.

“The acquisition Kohilo’s patent portfolio is a significant addition to Solarvest’s existing technology, which broadens our commercialization opportunities, and will enable us to operate unimpeded in several global markets”, said Gerri Greenham, CEO of Solarvest.

This transaction involves certain related parties and is exempt from shareholder approval accordance with MI 61-101 (Protection of Minority Security Holders in Special Transactions). Specifically, the principals of Kohilo are Mr. Mike Horne, who is also a director and secretary of Solarvest’s wholly owned European Subsidiary, Phycobiologics (Europe) Inc. and Mr. Garth Greenham who is the brother of Gerri Greenham, Director, CEO and control person of Solarvest. Additionally, certain of the debts of Kohilo to be assumed by Solarvest include Kohilo’s outstanding account with a law firm at which Kenneth A. Cawkell, Director, Chairman and Secretary of Solarvest, is a partner.

Concurrently with the close of this transaction, Garth Greenham has been appointed as Chief Operating Officer of Solarvest, subject to Exchange approval.

The common shares issuable pursuant to the purchase agreement will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation.

About Solarvest:

Solarvest is an algae technology company that owns numerous key patents and whose algal-based production platform provides it with an extremely flexible production system. The Company’s wholly owned subsidiary, Solarvest PEI, has developed a patented (pending) process to produce the world’s first organic Omega-3 using algae, to help meet the 13 billion dollar global Omega-3 market. The Solarvest system utilizes a natural process growing the algae under closely controlled conditions ensuring that the health product(s) produced have none of the environmental contaminants found in our oceans. Organic certification provides assurance that the product(s) is GMO free, sustainable, produced without chemicals and, being algae, supports vegetarian and vegan diets. Solarvest’s licensed Organic Omega-3 products will offer the consumer a healthy and sustainable product choice.

For further information contact: Gerri Greenham, Chief Executive Officer
Tel: 416 420 0947 Email: ggreenham@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Solarvest’s expectations and projections.

SOLARVEST TO ACQUIRE FOUR BIOACTIVE PATENTS

Montague, PEI, August 6, 2014 – SOLARVEST BIOENERGY INC. (TSX-V:SVS) (“Solarvest”), announces that it has entered an agreement to purchase worldwide rights to certain patents and patent applications from Kohilo Bio Inc. (“Kohilo”). Pursuant to the purchase agreement the total purchase price of \$102,642.75; \$70,000 of which will be paid through the issuance of 200,000 common shares at a deemed price of \$0.35 per share, and the balance of \$32,642.75 through the assumption of Kohilo’s debt.

This acquisition will strengthen and diversify Solarvest’s existing patent portfolio and will enable it to operate unimpeded in several global markets. In particular, this acquisition will give Solarvest complete worldwide rights to the Algae Technology Patent (System, Method below) that it previously licensed as a part of its Qualifying Transaction in 2008. This Algae Technology Patent particularly adds strength to Solarvest’s position as it relates to the creation of products by manipulating cell processes in the Algae. This will further strengthen Solarvest’s focus on using its unique Algae strains as a ‘manufacturing platform’ to produce a diverse range of products from vaccines and bioactive proteins to enzymes.

Solarvest now holds four complementary patents:

- o **SYSTEM, METHOD, AND DEVICE FOR THE EXPRESSION OR REPRESSION OF PROTEINS:** This invention manipulates algae cell processes.
- o **METHOD OF MAKING MICROALGAL-BASED ANIMAL FOODSTUFF SUPPLEMENTS, MICROALGAL-SUPPLEMENTED ANIMAL FOODSTUFFS AND METHOD OF ANIMAL NUTRITION:** This invention relates to use of algae as a safe, biodegradable food additive to effectively deliver trace metal essential nutrients to animals.
- o **DENTAL COMPOSITION AND METHOD:** This patent covers the use of algae and/or modified algae to control the growth of dental plaque on companion animals.
- o **METHODS AND USES OF A MODIFIED CECROPIN FOR TREATING ENDOPARASITIC AND BACTERIAL INFECTIONS:** This invention relates to the use of modified anti-microbial protein (cecropin and or variant of) or nucleic acid for treating or preventing endoparasites, such as Plasmodium (malaria parasite), and bacteria.

“The acquisition of Kohilo’s patent portfolio is a significant addition to our existing technology and broadens our commercialization opportunities,” said Gerri Greenham, CEO of Solarvest.

The use of Algae as a Technology platform provides Solarvest with a great advantage over traditional plant based production systems. Algae can be grown in controlled environments, which take advantage of their rapid growth rate, reducing the production cycle to a mere three or four days – up to 40 times faster than that of traditional crop systems.

This transaction involves certain related parties and is exempt from shareholder approval accordance with MI 61-101 (Protection of Minority Security Holders in Special Transactions). Specifically, the principals of Kohilo are Mr. Mike Horne, who is also a director and secretary of Solarvest's wholly owned European Subsidiary, Phycobiologics (Europe) Inc. and Mr. Garth Greenham who is the brother of Gerri Greenham, Director, CEO and control person of Solarvest. Additionally, certain of the debts of Kohilo to be assumed by Solarvest include Kohilio's outstanding account with a law firm at which Kenneth A. Cawkell, Director, Chairman and Secretary of Solarvest, is a partner.

Incidentally to this transaction, Garth Greenham will be appointed as Chief Operating Officer of Solarvest.

Completion of the acquisition will be subject to a number of conditions, including the approval of the TSX Venture Exchange. The common shares issuable pursuant to the purchase agreement will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation.

About Solarvest:

Solarvest BioEnergy Inc. is an algae technology company whose algal-based production platform provides it with an extremely flexible system capable of being adapted to produce clean energy in the form of hydrogen and health products such as Omega oils in an economic and environmentally sensitive manner.

For further information contact: **Gerri Greenham**, Chief Executive Officer

Tel: 416 420 0947 Email: ggreenham@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Solarvest's expectations and projections.